Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 12-Month Low Following Analyst Downgrade

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) reached a new 52-week low during trading on Tuesday after Zacks Research downgraded the stock from a strong-buy rating to a hold rating. The stock traded as low as $29.00 and last traded at $29.00, with a volume of 24,865 shares changing hands. The stock had previously closed at $41.92.

Other analysts also recently issued reports about the company. Jefferies Financial Group began coverage on Supernus Pharmaceuticals in a report on Wednesday. They set a “strong-buy” rating for the company. Weiss Ratings downgraded Supernus Pharmaceuticals from a “sell (d+)” rating to a “sell (d-)” rating in a report on Friday, October 30th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Piper Sandler assumed coverage on Supernus Pharmaceuticals in a research report on Wednesday. They set an “overweight” rating and a $47.00 price target on the stock. Finally, Cantor Fitzgerald lifted their target price on Supernus Pharmaceuticals from $67.00 to $87.00 and gave the company an “overweight” rating in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $63.50.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SUPN. BlackRock Inc. acquired a new position in Supernus Pharmaceuticals in the 2nd quarter valued at approximately $434,871,000. Bank of America Corp DE raised its holdings in Supernus Pharmaceuticals by 37.2% in the 1st quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock worth $36,918,000 after acquiring an additional 193,479 shares during the period. Ashford Capital Management Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 5.4% during the first quarter. Ashford Capital Management Inc. now owns 645,381 shares of the specialty pharmaceutical company’s stock worth $33,360,000 after buying an additional 32,843 shares during the last quarter. Rice Hall James & Associates LLC lifted its stake in shares of Supernus Pharmaceuticals by 2.0% in the first quarter. Rice Hall James & Associates LLC now owns 477,416 shares of the specialty pharmaceutical company’s stock valued at $24,678,000 after buying an additional 9,530 shares during the period. Finally, Systematic Financial Management LP boosted its stake in Supernus Pharmaceuticals by 23.6% during the first quarter. Systematic Financial Management LP now owns 376,079 shares of the specialty pharmaceutical company’s stock worth $19,440,000 after buying an additional 71,853 shares in the last quarter. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Supernus Pharmaceuticals Stock Up 0.2%

The business has a fifty day simple moving average of $41.74 and a two-hundred day simple moving average of $47.04. The company has a market capitalization of $3.33 billion, a price-to-earnings ratio of 7.88 and a beta of 0.84.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.49 by ($0.14). The business had revenue of $208.60 million during the quarter, compared to analyst estimates of $217.56 million. Supernus Pharmaceuticals had a negative return on equity of 418.04% and a net margin of 32.75%. The firm’s revenue was up 18.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.80) earnings per share. As a group, equities analysts predict that Supernus Pharmaceuticals, Inc. will post 3.66 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Announces Dividend

The company also recently announced a special dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 30th will be given a dividend of $8.13 per share.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.